Akari Therapeutics ( (AKTX) ) has released a notification of late filing.
Akari Therapeutics has filed a Form 12b-25, notifying a delay in submitting its Form 10-K (Yearly Report) for the financial period ending December 31, 2024. The primary reason for the delay is the need for additional time to finalize financial statements due to accounting complexities from a recent business combination and other accounting items. The company anticipates filing the report within the fifteen-day extension period allowed. Significant changes in financial results are expected, including increased operating expenses and net loss due to merger-related activities. Akari Therapeutics is committed to ongoing compliance, as indicated by the signature of its President and CEO, Samir R. Patel, M.D.
More about Akari Therapeutics
YTD Price Performance: 4.96%
Average Trading Volume: 36,445
Technical Sentiment Signal: Buy
Current Market Cap: $15.42M
See more insights into AKTX stock on TipRanks’ Stock Analysis page.